Navigation Links
Segment in Medical Technology

ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer

... segment fails to mention ongoing FDA-approved HIFU ... 16, 2008 edition of ABC News NIGHTLINE featured a segment on high intensity focused ultrasound (HIFU) for ... outpatient procedure for prostate cancer. The segment failed to mention that the Sonablate(R) 500 HIFU ...

Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device

... randomized, controlled phase of the trial. This segment is targeted to achieve the co-primary endpoints, ... by the Data Safety Monitoring Board, the third segment would permit the size of the trial to be ... of the trial are reached upon completion of segment two, extension of the trial ...

Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas

... the maximum tolerated dose (MTD) cohort expansion segment of its Phase 1/2a trial of RAV12, an ... RAV12 previously was chosen in a dose-escalation segment of the Phase 1/2a trial that involved 33 ... The recently concluded MTD Cohort Expansion segment involved 20 additional patients. The trial was ...

Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas

... in the maximum tolerated dose cohort expansion segment of its Phase 1/2a trial for patients with cancers ... targets the RAAG12 antigen. This segment of the trial will yield additional information ... schedule of RAV12 was chosen in a dose-escalation segment of the Phase 1/2a trial that involved 33 ....

The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy

... net sales increase for the Company's Cold Remedy segment of $1.0 million and $1.6 million, respectively, ... and development costs for the pharmaceutical segment and a reduction in gross profits from the Health ... stimulus. Net sales for the Health and Wellness segment declined $0.8 million and $3.9 million, ...

Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results

... two SBUs and the CSS group, Nabi has revised its segment reporting disclosures. Second quarter ... SUPPLEMENTAL segment INFORMATION (Unaudited, in ... (5,798) (7,735) (13,466) segment operating loss (1,723) (5,643) (4,297) ...

Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine

... 3 patients and the maximum tolerated dose (MTD) identified in the Phase I segment will be used in the Phase II segment of the study. Ann Cahill, Vice President, Clinical Development, ...

Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status

... panic attack. Alexza has completed the open-label, lead-in segment of the clinical trial, identifying the 1 mg AZ-002 dose as an ... and has initiated the randomized, double blind, placebo-controlled segment of the clinical trial. Alexza expects the enrollment of this clinical ...

Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned

... supply and demand from coronary artery disease. Unstable angina, non-ST segment elevation myocardial infarction (myocardial infarction which does not show ... for Management of Acute Coronary Syndrome without Persistent ST segment Elevation (JCS 2002, Circulation Journal Vol.66, Suppl. IV. 2002, ...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

... portfolio of respiratory products." Combination products containing inhaled corticosteroids and long-acting beta2-agonists are the largest segment of the worldwide market for asthma and chronic obstructive pulmonary disease (COPD) medications, in terms of dollar sales (1). The fixed-dose ...

Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference

... of the population, according to research reported at the Alzheimer's Association International Conference. This age group is the fastest growing segment of the population in western countries. This is different from past research results. Previous studies have suggested that the number of people with ...

Relievant Medsystems Announces Completion of $20 Million Financing

... day. "We were immediately attracted to Relievant's technology," said Hank Plain of Morgenthaler Ventures. "Their product addresses the largest segment of the back pain market with a relatively easy intervention that takes less than one hour to complete. We invested in Relievant for their potential ...

Spherix Announces Positive Phase 2 Study Results

... functional foods are foods with health-promoting or dietary management properties beyond the basic function of supplying nutrients and are a growing segment of the industry due to their increasing popularity with health-conscious consumers. About Spherix Spherix Incorporated was launched in ...

TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry

... devices. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TYRX is positioned to be an innovative applications leader in the space. For more information, please ...

Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers

... the Excellarate product candidate and the MATRIX clinical study click here (or visit Cardium's website at www.cardiumthx.com ). The television segment features the lead investigator of the study, Dr. Peter A. Blume, DPM, FACFAS, of the Yale University School of Medicine , and a patient enrolled in ...

Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis

... Abelson, M.D., Chairman and Chief Scientific Officer of Ora, Inc. "Patients with a history of chronic ocular background inflammation make up a large segment of the ocular allergy market, and are also patients that tend to evolve towards dry eye, another significant ocular disorder. In this study, they ...

SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production

... ST. LOUIS, April 23 /PRNewswire-FirstCall/ -- SAFC Biosciences(R), a business segment within SAFC(R), a member of the Sigma-Aldrich Group (Nasdaq: SIAL ), today announced the introduction of EX-CELL(TM) EBx (R) cell growth and viral ...

Pain Relief in Just One Visit with Genzyme's Synvisc-One

... Genzyme Biosurgery is positioned to benefit from this shift in preference. "The HA viscosupplementation market is the fastest-growing segment of the orthopedic biomaterial market, fueled in particular by the rise of single-injection treatments," says Kevin Flewwelling, Manager of the ...

WBAL Radio Segment With Dr. Leigh Vinocur Addresses Hope for the Rosacea Sufferer

... -- On March 9, 2009, Dr. Leigh Vinocur, medical expert from the University of Maryland School of Medicine , was featured on WBAL-AM 1090 in a segment on rosacea, a condition afflicting over 14 million Americans. Dr. Vinocur addressed current therapies while reporting on a new study conducted at ...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

... completed, not completed on a timely basis; the possibility that the acquisition of Indevus is not complementary to Endo; the potential that market segment growth will not follow historical patterns; general industry conditions and competition; business and economic conditions, such as interest rate and ...

First Swiss Patients Treated with the Percutaneous MitraClip(R) System

... said Ferolyn Powell, president and chief executive officer of Evalve. "The functional MR heart failure patient continues to be the fastest growing segment of the population undergoing treatment with the MitraClip(R) system and the initial commercial results in this population are very encouraging." ...

The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership

... The Quigley Corporation (Nasdaq: QGLY , http://www.Quigleyco.com ) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) lozenges, clinically proven to cut the common cold nearly in half. COLD-EEZE customers ...

Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments

... completed, not completed on a timely basis; the possibility that the acquisition of Indevus is not complementary to Endo; the potential that market segment growth will not follow historical patterns; general industry conditions and competition; business and economic conditions, such as interest rate and ...

ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology

... just published in IOVS, we were able to demonstrate excellent penetration of ESBA105, topically applied as eye drops to both anterior and posterior segment of the eye. In particular, topical administration of ESBA105 results in significant levels in the vitreous body which is of significant importance ...

Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration

... completed, not completed on a timely basis; the possibility that the acquisition of Indevus is not complementary to Endo; the potential that market segment growth will not follow historical patterns; general industry conditions and competition; business and economic conditions, such as interest rate and ...

Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults

... increase in the use of prescription sleep aids among all adults under age 45 from 1998 to 2006. The most dramatic increase was seen in the youngest segment of the study population, those between the ages of 18 and 24, whose prevalence of use increased from 599 users per 100,000 in 1998 to 1,524 users per ...

New Analysis Estimates Numbers of Older U.S. Adults Who May Benefit From Statin Therapy

... internist and fellow in the Robert Wood Johnson Clinical Scholars Program at Yale University , New Haven, Conn. "That's nearly 80 percent of this segment of the population who could potentially be recommended a statin therapy if those criteria were adopted into guidelines." The study is a ...

Pfizer Contributes Critical Data to URMC Drug Safety Initiative

... requires evidence of a drug's impact on the QT interval as one way to assess the cardiac risk associated with new compounds. The QT interval is a segment of an ECG recording that measures the process of ventricular repolarization. Prolongation of the QT interval associated with episodes of fatal ...

Infant Blood May Provide Insights into Diseases Present at Birth

... the entire population of U.S. infants and using the data for the retrospective study of disease. If a particular disease pops up in a specific segment of the population, you could use the data to look for causes, biomarkers and potential drug targets." All 50 states in the U.S. have ...

Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study

... PK study continues to support the premise that corticosteroids, delivered in low doses in a consistent and sustained manner directly into posterior segment of the eye, can be an efficacious treatment for DME," said Dan Myers, president and CEO of Alimera Sciences, "We are also pleased with Iluvien's ...

First FLEXUS(TM) Interspinous Spacer Surgeries for IDE Clinical Trial

... Ala., said, "The surgical technique and approach was very straightforward. The simplicity of the FLEXUS(TM) design in distracting the stenotic segment may be beneficial in treating this painful condition. We are excited to participate in this IDE." The 340 patient prospective, randomized ...

Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule

... with Contrave(R), now in Phase III clinical trials, these product candidates both have the potential to target a large, distinct and complementary segment within the obesity market." Orexigen is the only company currently developing two late-stage product candidates to address the full spectrum of ...

AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panel's Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.

... vs. only one trial. -- However, more physicians believe that the two trial implementation is the most appropriate. -- Even so, a segment of physicians (25% of cardiologists and 37% of endocrinologists) would support prescribing a new diabetes therapy that is highly efficacious ...

European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder

... medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit http://www.boehringer-ingelheim.co.uk . Duloxetine for major ...

Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH

... current Good Manufacturing Practices (cGMP) to production of quantities appropriate for initial human clinical trials. The PCR process produces a segment of DNA, called a linear expression cassette (LEC), which includes only those DNA sequences essential for eliciting immune responses. The bacterial ...

Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications

... Pacing technologies to market. These technology platforms resolve a number of respiratory clinical needs and create a neurostimulation market segment for these treatments. Clinical studies and research for other applications are ongoing. Candidates for this U.S. approval of the NeuRx DPS(TM) ...

Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers

... rise in the global incidence of diabetes and chronic vascular disorders, and a steady advancement in wound care technologies. The advanced wound care segment encompasses a wide range of disparate technologies that includes dressings and other devices. The three main categories for dressings are: ...

Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device

... June 13 /PRNewswire/ -- Disc Motion Technologies announced the completion of the first surgical procedure to implant the True Total Spinal Motion segment System (TM) (TSMS(TM)), the first total joint replacement system for the lumbar spine, featuring an artificial lumbar disc and posterior dynamic ...

Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials

... of 20% of consolidated sales, which amounted to euro 920.5 million while total revenues amounted to euro 993.8 million. Ipsen's shares are traded on segment A of Eurolist by Euronext(TM) (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the "Service de Reglement Differe" ("SRD") ...

Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial

... primary endpoints in COR-0002 were left ventricular diastolic relaxation indices as assessed by left ventricular pressure-volume loops and ST segment changes as assessed via electrocardiograms. The study concluded that HBOC-201 was indeed capable of preserving left ventricular function, likely ...
Other Contents
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
(Date:12/24/2014)... York, New York (PRWEB) December 24, 2014 ... ( http://www.xareltolawsuit2015.com/ ) that allege the blood thinner ... complications has outlined a leadership structure for the ... Order dated December 17th, the Court plans to ... the parties and also plans on appointing a ...
(Date:12/24/2014)... December 25, 2014 BambooIndustry.com a famous ... many years. Today, the company announces its multiple ... special offer on these new products. , Bamboo panel ... bamboo. The multiple layer bamboo panel board features high ... strong and emissions free. The bamboo panel consists of ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Adults ... higher risk of migraine headaches, suggests a study ... Neurology . "Childhood maltreatment can have long-lasting ... migraine in adulthood," study author Dawn Buse, director ... New York City, said in a journal news ...
(Date:12/24/2014)... Gluten, a protein found predominately in wheat ... intolerance to gluten, causing side effects that can range ... pain and fatigue. For this reason, Diet Doc created ... safe and fast weight loss while teaching patients how ... reaction. These gluten free diet plans combine the healthiest ...
Breaking Medicine News(10 mins):Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
Other TagsOther Tags